Artificial Intelligence | News | Insights | AiThority
[bsfp-cryptocurrency style=”widget-18″ align=”marquee” columns=”6″ coins=”selected” coins-count=”6″ coins-selected=”BTC,ETH,XRP,LTC,EOS,ADA,XLM,NEO,LTC,EOS,XEM,DASH,USDT,BNB,QTUM,XVG,ONT,ZEC,STEEM” currency=”USD” title=”Cryptocurrency Widget” show_title=”0″ icon=”” scheme=”light” bs-show-desktop=”1″ bs-show-tablet=”1″ bs-show-phone=”1″ custom-css-class=”” custom-id=”” css=”.vc_custom_1523079266073{margin-bottom: 0px !important;padding-top: 0px !important;padding-bottom: 0px !important;}”]

Galderma Announces the Launch of FACE by Galderma a Game-Changing Augmented Reality Solution Helping Healthcare Professionals Grow Their Activity and Improve Patient Satisfaction

Galderma has announced the launch of FACE by Galderma, an innovative augmented reality application. The ground-breaking solution enables aesthetic practitioners and patients to visualize treatment results at the planning stage. The technology will be presented to the aesthetic scientific community at the International Master Course on Aging Science (IMCAS) World Congress 2023 in Paris on January 26-28.

Recent AiThority News : AI Content Platform MetatronAI.com Announces New Features and Services

FACE by Galderma™ gives patients a real-time, realistic “before and after” view of possible results from an individualized treatment plan. This helps address concerns about end results while also enabling better understanding of a holistic treatment approach, ultimately leading to greater patient satisfaction1.

FACE by Galderma™ allows for an immersive, fully interactive consultation process and enables the aesthetic practitioner to evaluate the entire face in real time. The assessment is based on Galderma’s Five Facet Assessment that considers skin quality, facial shape, facial symmetry, facial proportions, and contour, as well as animation and emotional expression. Following the assessment, priority areas can be identified, and an individualized treatment plan can be created. By taking a full-face approach, FACE by Galderma™ ensures that the practitioner provides a holistic treatment plan that meets the patient’s needs. The technology behind FACE by Galderma™ was developed in partnership with Crisalix, the worldwide leading reference in 3D, virtual reality and augmented reality aesthetic simulation.

The results of a recent global pilot study of FACE by Galderma™ were extremely promising. Of the respondents, 80% said the application helped them to understand their treatment options, while 73% agreed that it made them contemplate a procedure they had not previously considered. Meanwhile, 61% stated that they plan to show their “before and after” images to friends. Overall, 85% said they would recommend the application, and 91% said they plan to return to their practitioner to continue their individualized treatment plan1.

Related Posts
1 of 40,659

AI News: Microsoft and OpenAI extend Partnership to Bring Supercomputing at Center of AI-powered Experiences

FACE by Galderma™ features 19 potential injectable results using products from the Galderma portfolio (depending on local indications), enabling patients to see simulated visuals in real time. Treatment options include:

  • Neuromodulators, such as DYSPORT®, AZZALURE® (EU) and ALLUZIENCE® (the first ready-to-use liquid botulinum toxin type A, approved in June 2021 for use in Europe (excluding Greece, Lithuania, Estonia, Latvia and Hungary)).
  • Biostimulators, including SCULPTRA®
  • Products from the hyaluronic acid filler range, RESTYLANE® and RESTYLANE® SKINBOOSTERS

The tool also facilitates patient management, acting as a “patient passport.” It enables clinics to store all patient records in one place, including the treatment plan, “before and after” video and images, and appointment schedules. Patients can also access their FACE by Galderma™ account and view their individual patient profile from home.

 Latest Aithority Insights : One AI Collaborates with AWS to Provide Language AI Solution for Developers

 [To share your insights with us, please write to sghosh@martechseries.com] 

Comments are closed.